Enhancing Urology: Silodosin Recordati’s Impact on Prostate Health

Verantwortlich: Nora Steinfeld, ad hoc news Fachredaktion Neuheiten & Launch. Geprueft am 30.06.2026, 19:24 Uhr. Details im Impressum.

Silodosin Recordati comes as a small white film-coated tablet, dispensed by urologists to help men facing prostate-related issues. Each tablet contains 8 mg of Silodosin, aimed at significantly improving daily life for those suffering from prostate enlargement symptoms. According to product manager Marta Rossi, this medication is a vital component in Recordati’s European urology portfolio.

What Silodosin Recordati Offers

Silodosin Recordati is a generic medication featuring Silodosin as its active ingredient. This selective alpha-1A-adrenoceptor antagonist is specifically designed to treat symptoms of benign prostatic hyperplasia (BPH). Available in 4 mg and 8 mg strengths, the 8 mg dosage is particularly recognized within German pharmaceutical information and pricing lists. The recommended standard dosage is one tablet daily, preferably taken with meals, as stated in the European Summary of Product Characteristics.

Recordati markets Silodosin Recordati across several EU nations, with the product information accessible via the pharmaceutical directory listing respective PZN numbers. This prescription-only medication is tailored for adult males experiencing moderate to severe lower urinary tract symptoms caused by prostate enlargement. Its approval is based on bioequivalence to reference Silodosin products as documented in EU professional publications.

Recordati’s Urology Focus

As a European pharmaceutical manufacturer based in Milan, Recordati focuses on specialist therapies, including urology and rare diseases. CEO Andrea Recordati emphasizes in investor presentations how generic products like Silodosin Recordati contribute to stable cash flows within the core portfolio. This product strengthens existing offerings against prostate and bladder issues, thereby expanding Recordati’s presence in clinics and practices.

The marketing strategy for Silodosin Recordati involves collaboration with local subsidiaries and partner companies, targeting general practitioners and urologists as primary prescribers. For patients, the daily convenience of the small pill and quick symptom relief are key factors, as highlighted in studies regarding Silodosin in BPH therapy. The product’s reliance on an established active ingredient also minimizes clinical risks.

Therapeutic Perspective and Patient Experience

During consultations, urologists explain to patients how Silodosin Recordati reduces the tension in the smooth muscle of the prostate and urethra. Patients often report symptoms like nocturia, a weak urine stream, and the sensation of incomplete bladder emptying—all common indicators of BPH outlined by European guidelines. Typically, Silodosin enhances urinary flow within days, while the actual size of the prostate remains unchanged.

Consistency in medication timing is crucial, ideally at the same time each day with a meal, to mitigate pharmacokinetic variability. Many patients do experience dizziness or orthostatic hypotension when rising, prompting urologists to explicitly inform them before starting therapy. Another prevalent side effect is retrograde ejaculation, which may unsettle men; clear communication can alleviate concerns by clarifying that this effect is known within the drug class and does not cause permanent harm.

Silodosin in the Competitive BPH Treatment Market

Belonging to the alpha-1 blocker group, Silodosin competes with medications like Tamsulosin and Alfuzosin. Its high selectivity for alpha-1A receptors in the prostate offers a significant advantage in mitigating urogenital symptoms, while minimizing cardiovascular side effects compared to less selective alternatives. Studies indicate that Silodosin notably lowers the International Prostate Symptom Score (IPSS) and increases the maximum urine flow rate.

As a well-established molecule in clinical settings, Silodosin faces competition from generic manufacturers in various markets. Silodosin Recordati must establish itself through pricing, availability, and active medical support. In some countries, this product is also available in combination with 5-alpha-reductase inhibitors, though such combinations typically operate under separate product names. Recordati’s strategy emphasizes maintaining a presence within existing active ingredient sectors to ensure a reliable revenue stream.

Regulatory Information and Product Guidelines

Silodosin Recordati’s approval is based on EU-wide harmonization of product information, detailing the mechanism of action, dosage, contraindications, and side effects. It is contraindicated in severe liver dysfunction and pronounced kidney impairment; alternative therapies or dosage adjustments may be required. Patients with significant cardiovascular histories should be monitored closely, given alpha-blockers’ potential to lower blood pressure.

Additionally, the product information highlights the risk of intraoperative floppy-iris syndrome during cataract surgery when under alpha-blocker therapy. Eye surgeons should be informed of Silodosin use beforehand, enabling adjustments in surgical techniques. This intersection between urology and ophthalmology exemplifies how medications may bridge multiple specialties. Recordati provides product and patient information via its subsidiaries.

Pricing, Reimbursement, and Market Position

In Germany, Silodosin Recordati is reimbursed under statutory health insurance if prescribed by a healthcare provider. Pricing lists feature various package sizes, such as 30 or 90 film-coated tablets of 8 mg, positioned in the lower to mid-range of BPH treatment costs. Discount agreements between health insurers and generic manufacturers may further enhance the product’s position in prescribing practices.

Across Europe, pricing varies according to national reimbursement systems, yet generic Silodosin products are often viewed as cost-effective alternatives to brand-name drugs. Recordati leverages its expertise in marketing prescription medications to seamlessly integrate Silodosin Recordati into standard care. For general practitioners, the familiarity of the active ingredient and known side effects reduces apprehension around prescribing it.

Significance for Recordati Stocks

While not a blockbuster, Silodosin Recordati serves as a consistent revenue generator in the established urology segment for Italian Recordati S.p.A. The product stabilizes cash flow within the generics sector, allowing the company to invest in rare diseases and novel specialty therapies. Recordati shares are traded on the Borsa Italiana in Milan, with stock prices reflecting a balance of solid generics revenues and growth-oriented niche products.

This article has been generated with AI support and editorial review. Product information is not guaranteed; prices and availability are subject to change. No investment advice, purchase, or sale recommendations are provided. Stock trading involves risks, including total loss.